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Abstract
Background: Public data integration may help overcome challenges in clinical implementation of microarray profiles. We
integrated several ovarian cancer datasets to identify a reproducible predictor of survival.
Methodology/Principal Findings: Four microarray datasets from different institutions comprising 265 advanced stage
tumors were uniformly reprocessed into a single training dataset, also adjusting for inter-laboratory variation (‘‘batch-
effect’’). Supervised principal component survival analysis was employed to identify prognostic models. Models were
independently validated in a 61-patient cohort using a custom array genechip and a publicly available 229-array
dataset. Molecular correspondence of high- and low-risk outcome groups between training and validation datasets was
demonstrated using Subclass Mapping. Previously established molecular phenotypes in the 2nd validation set were
correlated with high and low-risk outcome groups. Functional representational and pathway analysis was used to explore
gene networks associated with high and low risk phenotypes. A 19-gene model showed optimal performance in the
training set (median OS 31 and 78 months, p,0.01), 1st validation set (median OS 32 months versus not-yet-reached,
p = 0.026) and 2nd validation set (median OS 43 versus 61 months, p = 0.013) maintaining independent prognostic power in
multivariate analysis. There was strong molecular correspondence of the respective high- and low-risk tumors between
training and 1st validation set. Low and high-risk tumors were enriched for favorable and unfavorable molecular subtypes
and pathways, previously defined in the public 2nd validation set.
Conclusions/Significance: Integration of previously generated cancer microarray datasets may lead to robust and widely
applicable survival predictors. These predictors are not simply a compilation of prognostic genes but appear to track true
molecular phenotypes of good- and poor-outcome.
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Introduction
Epithelial ovarian cancer (EOC) presents an example of the
promise and challenges of using microarray analysis for prognostic
biomarker research. Based on its highly heterogeneous clinical
course [1,2,3] (even within advanced EOC, which represents over
70% of cases) and the modest discriminatory power of conven-
tional prognostic factors (amount of residual disease after initial
surgery, age, tumor grade, and histologic subtype [1,4,5]),
microarray studies were pursued in an attempt to account for
the molecular and biologic complexity of the disease [6,7,8,9,10].
However, none produced a gene expression signature that has
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been appropriate for clinical use. This is largely due to, among
other reasons, variable or small sample size, lack of adequate
validation, or inclusion of subtypes (clear cell, mucinous, papillary
EOCs), which constitute distinct molecular entities [11]. While
collectively these studies may be sufficient to identify useful
signatures, combining data or the analytical results is difficult for
many reasons, including the use of a variety of array platforms,
different data normalization and analysis approaches, and variability
in experimental protocols and patient selection. Finally, in many
instances it is not clear if the prognostic signatures reflect
reproducible stable disease phenotypes or are simply a combination
of prognostic genes. These limitations, which are not unique to
ovarian cancer, demonstrate the challenges limiting the application
of microarray signatures in cancer care and research, especially in
cancers with more limited availability of appropriate tissue resources.
In an effort to address these challenges, we assembled, curated,
and processed a collection of 265 raw gene expression arrays from
four previously reported ovarian cancer microarray studies
[10,12,13,14] applying consistent data normalization, quality
control, and analytical methods. A multi-gene model was
identified in this composite set that was then independently
validated in two separate tumor cohorts, one of which was profiled
on a custom array genechip and the other was a publicly available
standard oligonucleotide array dataset [15]. Finally, we showed
that this multi-gene model is not simply prognostic of outcome but
reflects reproducible ovarian cancer phenotypes and appears to
simultaneously track deregulation of several biological or onco-
genic pathways in this disease.
Results
Development of multi-gene prognostic classifiers in the
integrated training set
Figure 1 shows the workflow of our study (consort diagram). We
designed a custom array gene chip that included approximately
650 top performing candidate genes identified by applying the
supervised principal component survival analysis in each of the
four previously reported datasets. Then, we combined all four
microarray datasets into a composite training set (excluding 39
outlier samples), which consisted of 239 tumor arrays (Table 1,
Figure 1). Hierarchical clustering in the combined training set
revealed that, before application of the batch adjustment
algorithm, each dataset clearly separated from all the others
reflecting non-biological experimental variation (‘‘batch effect’’),
whereas after adjustment for batch effect, tumor samples from all
datasets were well intermixed (Figure 2).
We subsequently used the pool of the 650 marker genes (without
knowledge of their performance on the custom array) in order to
generate multi-gene prognostic classifiers in the combined training
set. Genes associated with survival (p,0.05) were ranked based on
their absolute Cox regression coefficients, and prognostic models
with the top ranking genes were developed using supervised
principal component survival analysis [16].
Since our goal was to develop oligogene prognostic signatures
we first identified models with the lowest number of genes that
could provide prognostic information in the integrated training set.
Models with as few as 2 genes distinguished between a high and a
low-risk group for survival in the combined training set (HR=1.7,
p = 0.003). Then, we evaluated models with higher number of
genes in the training set and noticed progressively increased
hazard ratios (HRs) until there was a plateau, with stable,
statistically significant HRs between 14 and 19 genes (i.e.
HR=2.1–2.3, p,0.001). Of these models, the 19-gene model
showed the best prognostic performance as evident by its higher
hazard ratio compared to the others. The best prognostic model
(19 genes, Table 2) distinguished between a high and a low-risk
group (median OS 31 and 78 months respectively, log rank
p,0.01, permutation p= 0.02) (Figure 3).
Independent validation of the multi-gene prognostic
classifiers
The 19-gene prognostic classifier was applied without any
further modification to the 1st validation set which included
expression data obtained from an independent cohort of advanced
stage ovarian cancers (Table 1, n = 61) using our custom array
containing the 650 previously selected genes; these genes had been
selected without prior knowledge about their prognostic perfor-
mance in the validation set. The 19-gene model distinguished
between a high and a low-risk group (median OS 32 months
versus not-yet-reached respectively, log rank p= 0.026, at 33
months median follow up, Figure 3). Of note, when we prioritized
the 19 genes based on their correlation with the principal
components of the dataset or the weight of their contribution to
the model, classifiers including the top 8–19 genes were also
prognostically valid in the 1st validation set (Text S1).
The 19-gene prognostic classifier was also applied without any
further modification to the 2nd validation set which included
expression data from 229 ovarian cancers (Table 1, n= 229).
Again, the 19-gene model distinguished between a high and a low-
risk group (median OS 43 months versus 61 months respectively,
log rank p= 0.013, Figure 3). Similar to the 1st validation set, when
we prioritized the 19 genes based on their correlation with the
principal components or their weight of contribution to the model,
several classifiers including the top 8–19 genes were also
prognostically valid in the 2nd validation set (Text S1).
Importantly, we tried to reproduce the prognostic power of two
previously reported signatures, from the BIDMC and DUKE
datasets, respectively [6,10]. Neither signature was reproducible in
either of the two independent validation sets (Text S1). Reasoning
that this may be due to different analytical algorithms applied in
the previous studies, we attempted to build new signatures using
the supervised principal component survival method separately in
each of the 4 datasets that comprised the integrated training set.
Again, none of these signatures could be validated in either of the
two independent sets (Text S1). These observations underscore the
value of integrating multiple expression datasets in order to derive
widely reproducible signatures.
Independent prognostic significance of the classifier
adjusted for known clinical and pathologic prognostic
factors
We performed multivariate analysis and formally established
that the 19-gene model maintained independent prognostic
significance adjusted for confounding factors, in both training
and the two independent validation sets (Figure 4A and Table 3).
Specifically, the Hazard Ratio (HR) of death for the unfavorable
versus the favorable group was 2.47 in the training set (95% CI,
1.71 to 3.56; p,0.01), 2.2 in the 1st validation set (95% CI, 1.01 to
7.76; p = 0.04), (Figure 4A) and 1.59 in the 2nd validation set (95%
CI, 1.05 to 2.4; p = 0.03), (Table 3). Because only 8/229 (3%) of
the tumors were definitely known to be suboptimally debulked in
the 2nd validation set, debulking status was included in the
multivariate analysis of the 2nd validation set as ‘‘grossly visible’’
versus ‘‘no visible’’ residual disease after surgery. Notably the
independent prognostic value of the profile held true regardless of
whether low grade was defined as grade 1 or grade 1 and 2 disease
(Table 3).
Integration of Ovarian Cancer Microarray Datasets
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Data on chemotherapy response were available only for the 1st
validation set. When we included chemotherapy response (i.e.
achievement of complete clinical response (CCR) after first line
chemotherapy versus no achievement of CCR) in the multivariate
analysis for the 1st validation set, the 19-gene profile maintained
its independent prognostic significance (HR=3.96, 95% C.I.
1.56–10.1;p = 0.004).
Figure 4B also shows that the 19-gene profile was still prognostic
of OS when applied in the homogeneous subsets of patients with
optimal and suboptimal debulking status in the training set. This
subset analysis could not be performed in the 1st validation set
because of sample size limitations, and in the 2nd validation set
because only 8/229 tumors (3%), were definitely known to be
suboptimally debulked.
Gene expression models and debulking status were the strongest
independent predictors of survival; therefore we were interested to
assess their combined prognostic power, which is also shown in
Figure 4C. Notably, the combination of optimal debulking and
low-risk 19-gene profile was associated with a median OS of 119
months in the training set and not-yet-reached in the 1st validation
set, while the combination of suboptimal debulking and high-risk
19-gene profile was associated with a median OS of 23 months in
the training set (HR=7.3, 95% C.I. 3.4–13.5) and 21 months in
the 1st validation set (HR=5.8, 95% C.I. 2.1–16) demonstrating
that the combination of the two variables is much more powerful
than either of them individually. This combination could not be
assessed in the 2nd validation set because only 3% of the tumors
were definitely known to be suboptimally debulked.
Figure 1. Consort Diagram (Study work flow). Raw data (Affymetrix .CEL files) from four previously reported microarray datasets from different
institutions were used. Outlier samples were excluded and batch effect was adjusted resulting in the final training set (239 arrays). 650 genes were
selected by performing survival analysis in each dataset and were used to develop prognostic models in the final training set. Data pre-processing
(quality control and batch adjustment) and normalization resulting in an integrated training set was done separately from the selection of 650 genes,
which were chosen independently by performing survival analysis in each of the 4 datasets (MD ANDERSON, PENN, DUKE, BIDMC). These preselected
650 genes were then used to develop prognostic models in the unified training set. These models were independently validated in two independent
datasets: a 61-tumor cohort using a custom array containing the 650 preselected genes and a 229-tumor recently published ovarian cancer
microarray dataset. The correspondence of the low- and high-risk phenotypes was assessed using SubMap.
doi:10.1371/journal.pone.0018202.g001
Integration of Ovarian Cancer Microarray Datasets
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Genome-wide molecular correspondence of high and
low-risk groups between the training and validation sets
It is frequently unclear if prognostic gene expression models are
surrogates for underlying wider molecular or biological pheno-
types, or simply a combination of individual prognostic genes. In
order to test the hypothesis that our prognostic models are tracking
molecular phenotypes of high versus low risk ovarian cancer, we
used a methodology (Subclass Mapping-SubMap) that is uniquely
suitable to assess the genome-wide molecular correspondence of
pre-specified subtypes in independent and even technically
disparate datasets [17]. Specifically, we investigated whether high
or low-risk tumors in the combined training set were molecularly
homologous with high or low-risk tumors in the 1st validation set,
above and beyond the handful of genes contained in the models.
This is done by demonstrating enrichment of the gene profile of
the ‘‘high risk’’ (or ‘‘low risk’’) group in the training set for a large
number of markers genes for the ‘‘high risk’’ (or ‘‘low risk’’) group
in the validation set and vice versa. As shown in Figure 5A, for the
19-gene model, high and low-risk tumors in the combined training
set corresponded with high degree of statistical certainty with high
and low-risk tumors respectively in the validation set (Table S1).
This result was reproduced using various subsets of marker genes
for the 19-gene model.
For the 2nd validation dataset, favorable (C3 and C6) and
unfavorable (C1, C2, C4, C5) prognostic molecular subtypes had
already been defined by the authors [15]. We therefore assessed
whether these previously defined molecular subtypes were
reproduced in the low and high-risk groups as defined by our
19-gene profile in the 2nd validation set (Figure 3). Indeed, in the
2nd validation set, the low risk group (as defined by the 19-gene
profile) was enriched for the favorable (C3 and C6) subtypes and
the high-risk group was enriched for the unfavorable subtypes, as
previously defined [15] (2-sided Fisher’s exact p = 0.0016).
Pathway analysis in high and low-risk disease groups
In order to gain insight into the pathway complexity of high and
low-risk disease, we performed pathway and representational
analyses to identify annotated pathways and functional gene
groups that were overrepresented (enriched) in the gene profiles of
the two risk categories in the large training set (the custom array,
by design, contained too few genes to perform this analysis in the
validation set).
GSA pathway analysis was performed over a wide range of
differentially expressed genes between high and low-risk groups
[using a t-test p from 0.01 (3264 genes) to as low as 0.0001 (1698
genes)], and revealed eight pathways (Figure 5B) that were
consistently statistically significantly differentially expressed (Efron-
Tibshirani GSA test p ,0.05).
We also performed functional representational analysis using
EASE among genes that were upregulated and downregulated in
Table 1. Clinical and Pathological Characteristics of Training and Validation Cohorts.
Clinical and Pathological characteristics
INTEGRATED
TRAINING a 1st VALIDATION 2nd VALIDATION
Patients (n =239) Patients (n =61) Patients (n =229)
Characteristic No. % No. % No. %
Age Median 58.5 63 59.3
Range 36–82 44–84 23–80
Grade I 9 4 0 0 0 0
II 67 28 5 8 85 37
III 144 60 56 92 144 63
Debulking
Status b
Optimal 101 42 43 70 129 56
Suboptimal 110 46 18 30 8 3
Stage c 1 0 0 0 0 12 5
2 0 0 0 0 12 5
3 204 85 47 77 191 83
4 34 14 13 21 14 6
Histology Serous 230 96 60 98 216 94
Endometrioid 9 4 1 2 13 6
Chemotherapyd Platinum-Taxane 175 73 61 100 171 75
Platinum-Cytoxan 51 21 0 0 0 0
Platinum alone 2 1 0 0 45 20
No chemotherapy 0 0 0 0 13 6
aData were not available for all patients in the integrated training set (grade was not available for 19 pts, debulking status for 18 pts, stage for 1 pt and chemotherapy
for 11 pts).
b8/229 (3%) of the tumors were definitely known to be suboptimally debulked in the 2nd validation set. 129/229 (56%) were optimally debulked. 61/229 (27%) had
,2 cm residual disease after surgery but is unclear how many had ,1 cm, and for 31/229 (14%) debulking status was unknown.
cStage was not available for one patient in the training and for 1 patient in the 1st validation set.
dChemotherapy information was not known in the training set for 11 patients.
doi:10.1371/journal.pone.0018202.t001
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the high- versus low-risk patients (using a t-test p,1026). We
found 22 and 54 pathways overrepresented among genes
upregulated and downregulated in high-risk tumors respectively
at a within-system FDR threshold of 0.01. A full list of these
pathways is found in Tables S2, S3 and S4, while selected
pathways are presented in Figure 5B.
Interestingly, several of these pathways (Figure 5B), that were
upregulated in high risk tumors i.e. ‘‘cytokine-cytokine receptor
interaction’’, ‘‘cell communication’’, ‘‘ECM-receptor interaction’’,
‘‘pathogenic invasion’’, ‘‘cell growth’’, and low risk tumors i.e.
‘‘differentiation’’, were also similarly expressed in the high and low-
risk tumors as previously reported in the 2nd validation set [15].
Figure 2. Adjustment for non-biological experimental variation. Multidimensional scaling of the combined training set revealed that, before
application of the batch adjustment algorithm, each dataset clearly separated from all the others (‘‘batch effect’’), whereas after correction of batch
effect, samples from all datasets were well intermixed.
doi:10.1371/journal.pone.0018202.g002
Table 2. Genes and Probe Sets That Constitute the 19-Gene Model.
GENE SYMBOL PROBESET GENE NAME
INVS 210114_at Inversin
CACNG1 206612_at calcium channel, voltage-dependent, gamma subunit 1
ANXA2P1 210876_at annexin A2 pseudogene 1
NEBL 217585_at Nebulette
PAGE1 206897_at P antigen family, member 1 (prostate associated)
MPZL2 203780_at myelin protein zero-like 2
MAP3K10 206362_x_at mitogen-activated protein kinase kinase kinase 10
H6PD 206933_s_at hexose-6-phosphate dehydrogenase (glucose 1-dehydrogenase)
ANXA2P3 211241_at annexin A2 pseudogene 3
CAMP 210244_at cathelicidin antimicrobial peptide
PLD2 209643_s_at phospholipase D2
CTSZ 212562_s_at cathepsin Z
SLC12A4 209401_s_at solute carrier family 12 (potassium/chloride transporters), member 4
RBP3 210318_at retinol binding protein 3, interstitial
TPO 210342_s_at thyroid peroxidase
LBX1 208380_at ladybird homeobox 1
ASGR1 206743_s_at asialoglycoprotein receptor 1
DMN 214304_x_at Desmuslin
KRT31 206677_at keratin 31
doi:10.1371/journal.pone.0018202.t002
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Prognostic gene expression models reflect activation of
known oncogenic pathways in individual tumor samples
Given that GSA or EASE cannot assign pathway activation
status for individual tumor samples, we applied previously
developed gene expression ‘‘readouts’’ resulting from experimen-
tally controlled activation of specific oncogenic pathways (src, b-
catenin and E2F3) that have been shown to bear prognostic
relevance in ovarian cancer [12]. We discovered that in the 239-
tumor training set, the odds-ratios of activation of src and b-catenin
pathways in our high versus low-risk group were 3.42 (95% C.I.
1.89–6.18) and 2.77 (95% C.I. 1.59–4.8) respectively, while the
odds-ratio for E2F3 was 0.251 (95% C.I. 0.141 – 0.446). This is
consistent with previous studies indicating that activation of src and
b-catenin pathways are associated with poor outcome while
activation of E2F3 is associated with good outcome, and indicates
that our analysis captures biologically relevant information that is
not immediately obvious by examining the content of the 19-gene
profile. In multivariate analysis including the 19-gene model and the
3 oncogenic pathways, the 19-gene model maintained independent
prognostic significance, whereas the activation patterns of the
oncogenic pathways did not (data not shown).
Discussion
Although the suitability of gene expression profiling for
prognostication has been demonstrated in ovarian cancer
[6,8,10], several challenges must be addressed before it becomes
a clinically useful tool. Previous prognostic microarray studies were
limited by sample size, interlaboratory variability, lack of external
(out of study) validation, non-standardized analytical approaches
Figure 3. Association between 19-gene model and overall survival in the training and validation sets. The 19-gene model distinguished
between a high and a low-risk group in the training set with a median OS of 31 months and 78 months respectively (log rank p,0.01, permutation
p= 0.02), a high and a low-risk group for OS in the 1st validation set (median OS 32 months versus not-yet-reached respectively, log rank p= 0.026),
and a high and a low-risk group for OS in the 2nd validation set (median OS 43 months versus 61 months respectively, log rank p= 0.013).
doi:10.1371/journal.pone.0018202.g003
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and inclusion of histologic subtypes with distinct genetic profiles
and outcome (i.e. clear cell, and mucinous cancers) [11]. In this
study we described a successful pipeline that may also be useful for
similar efforts in other cancers. We reprocessed and integrated raw
data from four separate, previously generated microarray datasets
[10,12,13,14] originating from different laboratories and run on
different platforms, into a large and homogeneous set, excluding
mucinous and clear cell EOCs, thus maximizing our power to
identify robust profiles while minimizing false positive findings. We
corrected the non-biological experimental variation (‘‘batch
effect’’) [18], which was clearly evident across studies (Figure 2)
and composed a final training cohort of 239 tumors. We also used
a standardized survival analysis method that compares favorably
to other methods applied on microarray data [16,19]. The
resulting prognostic model was validated twice, in two separate
independent sets. This is the first time, to our knowledge, that this
has been attempted in this disease. Tumors included in the two
validation cohorts originated from different institutions and were
run in different laboratories and time periods than the tumors
included in the combined training cohort. A custom chip was used
for the 1st validation set, and a large publicly available whole-
genome dataset was used as a 2nd validation set, while the training
samples were previously run on different (whole-genome) plat-
forms many years earlier. In addition to the rigor of this validation
process, our use of publicly available datasets and of a customized
design chip minimizes the cost of introducing gene-profiling
technology to routine clinical practice.
A 19-gene model with optimal prognostic performance in the
training set discriminated between a high and a low-risk group for
OS in the two validation sets, while maintaining its independent
association with survival in multivariate analysis adjusting for
known clinicopathologic confounding factors. Of note, previously
reported gene expression signatures from individual component
datasets of the training set [6,10], or newly generated models using
our current methodology in these datasets, were not reproducible
in either of the two independent validation datasets. This suggests
Figure 4. Independent prognostic significance of the multigene classifiers adjusted for known clinical and pathologic prognostic
factors. A) Prognostic value of the 19-Gene expression profile adjusted for known prognostic factors by Cox Proportional Hazards Regression in the
training and 1st validation sets. B) Kaplan-Meier analysis for OS as a function of the 19-gene profile for homogeneous subsets of patients with optimal
and suboptimal debulking status in the training set. C) The combination of optimal debulking and low-risk 19-gene profile was associated with a
median OS of 119 months in the training set and not-yet-reached in the validation set, while the combination of suboptimal debulking and high-risk
19-gene profile was associated with a median OS of 23 months in the training set (HR= 7.3, 95% C.I. 3.4–13.5) and 21 months in the 1st validation set
(HR= 5.8, 95% C.I. 2.1–16).
doi:10.1371/journal.pone.0018202.g004
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Table 3. Multivariate Analysis in the 2nd Validation Set.
19-Gene Profile Adjusted for Age, Grade, Stage and Residual Disease* in 2nd Validation Set
Prognostic Factor Univariate P Value Multivariate P Value
Age 0.035 (HR=1.56) 0.06
Gradea 0.452 0.96
Stage 0.267 0.205
Grossly Visible vs
No Visible
0.003 (HR=2.32) 0.008 (HR=2.21)
Gene Profile (high/low risk) 0.015 (HR=1.65) 0.03 (HR=1.59)
aGrade 1 tumors were removed from this dataset (Table 1). If we also remove grade 2 tumors from the 2nd validation dataset (as grade 2 disease can also be considered
low grade), the 19-gene profile was again associated with overall survival both in univariate (HR = 1.8, 95% C.I. 1.09–2.99) and multivariate analysis (HR = 1.91, 95% C.I.
1.13–3.26).
doi:10.1371/journal.pone.0018202.t003
Figure 5. A) Genome-wide molecular correspondence of high and low-risk groups between training and 1st validation set. SubMap
analysis of genome-wide correspondence (similarity) between respective high and low risks groups in the training and 1st validation set. The legend
shows the relationship between color and FDR-adjusted p-values. Red color denotes high confidence for correspondence; blue color denotes lack of
correspondence (Table S1). B) Functional gene set analysis and functional representational analysis in high and low-risk disease
samples. Gene set analysis (GSA) over a wide range of differentially expressed genes revealed 8 pathways that were consistently statistically
significantly differentially expressed. (Efron-Tibshirani GSA, p,0.05). Selected pathways-gene sets are shown that were overrepresented among high-
risk and low-risk tumors by functional representational analysis using EASE (within-system FDR #0.01). A full list of these pathways is found in Tables
S2, S3 and S4. Asterisks (*) denote pathways that were similarly expressed in corresponding prognostic groups in the 2nd validation set.
doi:10.1371/journal.pone.0018202.g005
Integration of Ovarian Cancer Microarray Datasets
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that our strategy of integrating information from different and
technically disparate datasets into a composite training set
augments our ability to capture widely reproducible prognostic
gene expression patterns. The variability in Hazard Ratio
estimates for the 19-gene profile between the training and two
validation sets, likely reflects the differences between the various
clinical cohorts, whose characteristics are rarely identical in
microarray studies. For instance, the 2nd validation set appears
to overwhelmingly consist of optimally debulked, thus improved
prognosis patients. Nonetheless, this further underscores the
validity of the profile when applied to a wide range of ovarian
cancer patient populations.
Gene expression models were as powerful as debulking status,
the strongest known clinical predictor of survival in advanced
EOC [4], and the combination of optimal debulking and low-risk
profile defined a population with a long survival plateau (70% 5-
year survival in both training and 1st validation set). Conversely,
the combination of suboptimal debulking and high-risk profile
defined a population with only 10% 5-year survival. Such
powerful prognostic stratification in advanced EOC is not possible
using conventional clinical factors at the time of diagnosis and may
be useful for stratification of high-risk patients that are considered
for investigational approaches using maintenance and/or consol-
idation strategies, or low-risk medically unstable patients that may
avoid the relatively toxic intraperitoneal chemotherapy [20].
Our study also aimed to investigate wither the profile is not
simply a mathematical combination of 19 prognostic variables, but
is also tracking molecular phenotypes of high- versus low-risk
ovarian cancer. Using a methodology (SubMap) that is uniquely
suitable to assess the wider genomic resemblance of subtypes
identified in multiple, independent, and disparate datasets [17], we
confirmed that the low and high-risk groups assigned by our
prognostic models were molecularly homologous between training
and validation sets, suggesting that we have not simply validated a
mathematical prognostic function but also true molecular pheno-
types of good- and poor-outcome. In the 2nd validation set,
molecular outcome subtypes had already been established by the
authors [15]. Our finding that these molecular subtypes were
overrepresented (enriched) in the high and low risk groups identified
by our 19-gene profile, further attests to the notion that the profile is
tracking true and reproducible outcome phenotypes in EOC.
While it was beyond the scope of our study to investigate the
precise biological role of any specific pathway, it is noteworthy that
pathways that were upregulated in the high- risk group have been
implicated in ovarian carcinogenesis and/or associated with
aggressive disease and poor outcome [21,22,23]. Furthermore,
pathways that were overrepresented among genes overexpressed
in high-risk tumors have been also been associated with inferior
outcome [24,25,26], lending biologic plausibility to the phenotypes
we discovered. Importantly, several of these pathways (Figure 5B)
were also similarly expressed in the high and low-risk tumors
previously reported in the publicly available 2nd validation set,
demonstrating reproducibility of biological networks associated
with good and bad-outcome between the different datasets [15].
Finally, we took advantage of previously developed gene
expression ‘‘read outs’’ resulting from experimentally controlled
oncogenic pathway activation (src, b-catenin and E2F3) to assess
activation status in individual tumor samples [12,27]. Although
there is an ongoing debate about how the oncogenic pathway
analysis described by Bild et al. [12]. was applied in one particular
study [28], the original oncogenic pathway analysis method
described by Bild et al. has not been challenged. Consistent with
known prior data, src and b-catenin pathways were more
frequently activated in high-risk compared to low-risk tumors,
while the opposite was true for the E2F3 pathway [12,27,29]. The
novel association of the oncogenic pathway activation status with a
phenotype ‘‘captured’’ by a marker 19-gene profile, of which none
of the pathway genes is a member, demonstrates that biological
inference in microarray studies should not be limited to the
frequently applied approach of screening a list of top marker genes
in a prognostic signature. Of note, these oncogenic pathways lost
independent prognostic significance in multivariate analysis when
the profile was included, suggesting that our prognostic classifier is
capturing complex phenotypes and that outcome differences in
ovarian cancer may not be adequately explained by deregulation
of a single oncogenic or signaling pathway.
In conclusion, our approach exemplifies how integration and
disciplined analysis of the rich information content of published
but disparate cancer microarray datasets can overcome previous
limitations and lead to development of robust and potentially
widely applicable prognostic classifiers. A custom array may also
be a practical tool in the study and management of cancer. Our
study is consistent with, but provides complementary insight to
previous seminal work that demonstrated the reproducibility of
various gene expression profiles, when multiple array cohorts were
run simultaneously, using the same protocol, on the same
microarray platform in different laboratories [30].
The success of our approach does not negate the importance of
previous individual expression studies, which have identified gene
patterns with clinical and biologic relevance; rather effective
integration of these studies may represent an important step
forward towards wider clinical application of gene expression assays.
Materials and Methods
Synthesis of the combined training set
Raw gene expression profile data (Affymetrix .CEL files) were
retrieved from four previously reported clinically annotated micro-
array datasets from different institutions (Beth Israel Deaconess
Medical Center (BIDMC) [10], University of Pennsylvania (PENN)
[14], Duke (http://data.genome.duke.edu/oncogene.php) and
MD Anderson (http://www.mdanderson.org/departments/expther/
bastovcalab/) comprising 265 advanced stage (stages 3 and 4)
papillary serous ovarian cancers. These were profiled on Affymetrix
U95Av2 (BIDMC and MD Anderson), Affymetrix U133A (Duke)
and Affymetrix U133 Plus 2.0 (Penn) array platforms (the
hybridization protocols are commercially available, websites in
Text S1).
These were reprocessed uniformly and combined into a single
training dataset: First, signal intensity was normalized within each
individual dataset using Robust Multi-Array Average (RMA)
analysis. Probesets were mapped across different platforms using
Affymetrix annotation files and the Affymetrix ‘best match’ tool. In
order to minimize the possibility that there are experimental batch
effects that associate with OS within each individual dataset, we
performed unsupervised hierarchical clustering in each of the 4
datasets. In all cases, we observed 2 predominant clusters, and
there was no statistically significant difference in overall survival
between these 2 predominant clusters in any of the datasets.
Coinertia analysis [31] was performed in order to determine the
loss of information incurred by reducing the number of genes to
the subset common to the different Affymetrix platform. The
overall similarity between datasets in the set of common samples
was measured using a multivariate extension of the Pearson
correlation coefficient called the RV-coefficient. The RV-coeffi-
cient is calculated as the total co-inertia (sum of eigenvalues of a
co-inertia analysis) divided by the square root of the product of the
squared total inertias (sum of the eigenvalues) from the individual
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COAs. It has a range 0 to 1 where a high RV-coefficient indicates
a high degree of co-structure. When the subset of common genes
was examined, the RV co-efficient was 0.86 indicating that the
global correlation structure between datasets was not affected by
the reduction in genes. Hence we decided to just examine the
common genes in subsequent analysis.
Following normalization, technical outlier samples were iden-
tified and excluded using a model-based quality control assessment
that included relative log2 expression (RLE) measures, normalized
un-scaled standard errors (NUSE), array pseudo-images, and the
percent of probe sets called ‘‘present’’. Finally, systemic non-
biological interlaboratory experimental variation (‘‘batch effect’’)
between the datasets was adjusted using non-parametric empirical
Bayes frameworks implemented in ComBat (http://statistics.byu.
edu/johnson/ComBat) [18]. The resulting normalized, standard-
ized dataset contained 239 samples.
Independent Validation Sets
The 1st independent validation set included 61 patients with
advanced stage (III, IV) ovarian cancer diagnosed between 9/2001
and 7/2008 at BIDMC, Massachusetts General, and Brigham and
Women’s hospitals (Table 1). All patients underwent standard
surgical and chemotherapy treatment [1]. The study protocol for
collection and use of tissue and clinical information for all patients
was approved by the institutional review boards at Beth Israel
Deaconess Medical Center, Massachusetts General Hospital,
Brigham and Women’s Hospital and Dana Farber Cancer
Institute. All patients provided written informed consent autho-
rizing the collection and use of the tissue for study purposes.
Profiling was performed using a custom Affymetrix GeneChipTM
with 650 genes. After we had integrated the 4 aforementioned
datasets into one combined training set, and developed and
validated the prognostic models in the 1st independent validation
set using the custom Affymetrix GeneChipTM, another ovarian
cancer dataset became publicly available and thus we decided to
use it as a 2nd independent validation set (GSE9899) [15]. This
dataset included 229 patients with epithelial ovarian, primary
peritoneal, or fallopian tube cancer (after excluding patients with
grade 1 disease, and those with no survival data), diagnosed
between 1992 and 2006. Profiling was performed using Affymetrix
U133 Plus 2.0 arrays. The clinicopathologic characteristics for
both validation sets are shown in Table 1.
Design of Custom Array Chip
Gene-expression profiling in the 1st independent validation
dataset, was performed using a custom Affymetrix GeneChip (data
available at GEO, accession number GSE19161, http://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?token=bdgzfwmysouamxe&
acc=GSE19161). The number of probe sets on the custom chip
represents a compromise between cost and inclusion of an adequate
pool of top candidate prognostic genes, a priori identified by
applying the supervised principal component survival analysis
method in each of the individual training datasets. Specifically, we
applied supervised principal components analysis [16] in each
dataset and selected subsets of probe sets that created a maximum
significant survival split. Then, we applied the models to the
remaining training datasets and identified the maximum number of
probe sets that could also generate a significant survival splits in all
remaining training datasets. This analysis was repeated for the
different training datasets, ultimately generating a pool of markers that
was the union of probe sets resulting from these analyses. This pool,
including probe sets that were part of significant prognostic models in
all datasets, was selected for the custom array. We also added pre-
defined prognostic signatures from previous publications [6,10]. Next,
we screened the list for duplicates and if there were duplicates we
retained only the U 133-based probe set. Finally, we added a set of
control spikes and normalization probe sets. The total number of
probe sets was set to approximately 1200 (the precise number was
1191), based on the maximum number of probe sets that could be
custom-spotted at the minimal possible cost. The array contained a
total of 658 unique prognostic genes (excluding controls, averaging
probe sets that were duplicates of the same gene, and converting all
probe sets to the U 133 A platform). The design was carried out in
collaboration with the Affymetrix technical design team.
Development of prognostic models using the supervised
principal component survival algorithm
Firstly, genes associated with survival in the combined training
set at a significance level of 0.05 (Cox proportional hazards model)
were identified. More details are included in Text S1. These genes
were subsequently ranked based on their absolute Cox regression
coefficients, and prognostic models with several sets of top ranking
genes using the supervised principal component survival algorithm
were developed. The methodological principles of the Survival
Risk Prediction Algorithm have been previously described [16].
A high and a low-risk survival groups were defined based on a
multivariate model of the expression level of the genes contained
in each set of top ranking genes and the Cox regression coefficient
for each gene. This multivariate model was used in a leave-one-out
cross validation process to assign risk-group membership for
clinical samples. Kaplan-Meier OS curves were plotted for two
risk groups, with higher or lower than median risk of death or
recurrence. Statistical significance of the survival splits was
assessed by the log-rank test and a permutation statistic was
calculated by randomly reassigning the survival data among cases,
repeating the entire survival risk prediction 100 times and
estimating how many times the log-rank statistic is lower than
the log-rank statistic for the real data. This represented the
permutation significance level for testing the null hypothesis that
there is no relation between the expression data and survival.
These models were directly applied without any modification to
the two validation sets after adjustment of non-biological
experimental variation across data sets [18]. Multidimensional
plots of the training, validation 1 and validation 2 datasets, before
and after correction of batch effect show that before application of
the batch adjustment algorithm, each dataset clearly separated
from all the others (‘‘batch effect’’), whereas after correction of
batch effect, samples from all datasets were well intermixed (Figure
S1). All reported p-values are two-sided. Multivariate adjustment
for known prognostic factors was performed using a Cox
proportional hazards regression model that included grade, age
(,65 years versus $65 years), stage (early stage 1 or 2 versus
advanced stage 3 or 4), debulking status (optimal, less than or
equal to 1 cm.; or suboptimal, greater than 1 cm. residual disease)
and 19-gene profile risk status (low- vs high-risk). Because only 8/
229 (3%) of the tumors were definitely known to be suboptimally
debulked (based on the 1 cm cutoff criterion for debulking status)
in the 2nd validation set, debulking status was included in the
multivariate analysis of the 2nd validation set as ‘‘grossly visible’’
versus ‘‘no visible’’ residual disease after surgery.
Genome-wide molecular correspondence of high and
low-risk groups between the training and validation sets
using Subclass Mapping (SubMap)
In order to assess whether tumors assigned as high or low-risk in
the combined training set were molecularly homologous with
tumors assigned as high or low-risk, respectively, in the validation
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set, we used a recently developed methodology (Subclass
Mapping-SubMap) that is uniquely suitable to assess the
genome-wide molecular correspondence of pre-specified subtypes
in independent and even technically disparate datasets.
Submap is an unsupervised subclass mapping method that
identifies the correspondence or commonality of subtypes found in
multiple, independent data sets potentially generated on different
platforms. Suppose we have two independent datasets A and B
with i and j candidate subclasses respectively (a subclass must
contain at least 10% of the samples of a dataset to be considered as
a candidate subclass). Marker gene lists ‘marker(Ai)’ for each
candidate subclass in A (A1, …Ai) are determined based on the
differential gene expression versus the rest of A subclasses, while
genes in data set B are rank-ordered according to their correlation
with each Bj subclass versus the other B subclasses to yield a gene
list, ‘ranking(Bj)’. Association between Ai and Bj is evaluated by
quantifying the over-representation of ‘marker(Ai)’ in the up-
regulated end of the list ‘ranking(Bj)’ using Gene Set Enrichment
Analysis (GSEA) as previously described [32]. An enrichment
score (ESAiBj) is calculated, and statistical significance is assessed
as a p-value, pAiBj, by randomly permuting sample class labels in
B and estimating the null distribution of ESAiBj score. This
process is repeated by interchanging the role of A and B to
compute ESBjAi and pBjAi. Mutual enrichment information is
defined by combining pAiBj and pBjAi using the Fisher inverse
chi-square statistic, Fij. Statistical significance is estimated based
on a null distribution for the Fij generated by randomly picking the
p from corresponding null distributions for ESAiBj and ESBjAi. A
FDR adjustment to account for multiple hypotheses testing is
performed, and FDR adjusted p-values are summarized in the
subclass association matrix (SA matrix).
Pathway Analysis
In order to assess whether the gene expression profiles of high-
and low-risk disease samples were enriched for specific functional
groups of genes, we performed functional category representa-
tional analysis using EASE [33] among genes that were
upregulated and downregulated in the high- versus low-risk
patients (using a t-test p,1026). We analyzed representation of
Gene Ontology assignments, phenotype, PFAM, PIR, Swiss-Prot
keywords, GenMAPP and KEGG pathways. For each functional
category of genes we utilized a False Discovery Rate (FDR) of
#0.01 to assess the impact of multiple testing.
Furthermore, we performed gene set analysis (GSA) as
described by Efron and Tibshirani [34], which is an evolution of
the previously reported Gene Set Enrichment Analysis (GSEA).
GSA pathway analysis was performed over a wide range of
differentially expressed genes between high and low-risk groups
[using a t-test p from 0.01 (3264 genes) to as low as 0.0001 (1698
genes)], to identify pathways that were consistently statistically
significantly differentially expressed at a GSA p,0.05.
Prediction of probability of oncogenic pathway
activation in tumor samples
We used signatures of experimentally controlled oncogenic
pathway activation that are publicly available at http://dig.
genome.duke.edu/. These signatures have been validated in a
variety of in vitro models and patient samples. Specific
mathematical models based on the Bayesian probit regression
algorithm, estimating the probability of activation of each pathway
were trained in the experimental systems used to develop these
signatures (arrays available at the website indexed above) and
applied on individual tumor samples of the training set. Non-
biological experimental variation between the experimental system
arrays and the ovarian cancer datasets was corrected using a
previously described batch effect adjustment algorithm, ComBat
(http://statistics.byu.edu/johnson/ComBat) [18]. Each individual
tumor sample was assigned a probability value of pathway
activation, from 0 to 1. A probability value higher than 0.5 was
used as cut off for pathway activation. The association between
gene expression profile risk status (i.e. low versus high-risk) and
activation of oncogenic pathways in each tumor sample was tested
using 262 table statistics and Odds-ratios.
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and validation sets revealed that, before application of the batch
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samples from all datasets were well intermixed.
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